FluidForm Bio

FluidForm Bio is a private, preclinical-stage biotechnology company pioneering a novel 3D bioprinting platform called FRESH™. This platform uniquely prints cells and proteins in an aqueous environment to create complex, vascularized human tissues, with an initial focus on developing an implantable cure for Type 1 Diabetes. The company operates as a platform technology provider, partnering with life science firms while advancing its own lead program. Led by a team with deep expertise in medical technology and tissue engineering, FluidForm Bio aims to transform cell therapy by enabling long-term, minimally invasive implantable treatments.

FRESH™ (Freeform Reversible Embedding of Suspended Hydrogels) 3D bioprinting platform. It prints cells and natural proteins (e.g., collagen) into a temporary support bath to create complex, vascularized living human tissues without synthetic scaffolds.

FluidForm Bio competes in the crowded 3D bioprinting and regenerative medicine space with firms like Prellis Biologics (vascularization), Aspect Biosystems (bioprinting platforms), and larger players like 3D Systems and Cellink (BICO). Its key claimed differentiator is the FRESH method's ability to create high-fidelity, scaffold-free, vascularized tissues using only natural biological materials.